Based on 6 analysts giving stock ratings to Coherus BioSciences Inc in the past month.
In the current month, CHRS has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CHRS average Analyst price target in the last month is 7.000.
Based on analysts' estimates, CHRS EPS is projected to reach -0.220 in FY2026Q4, following reported EPS of -0.254 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.25, while Coherus BioSciences IncCHRS's earnings per share (EPS) for the previous quarter was USD -0.13. EPS for the next quarter is expected at USD -0.22.